The personalized medicine market is projected to grow from USD 524 billion in 2025 to over USD 1 trillion by 2034, fueled by advances in genomics, biomarker diagnostics, and AI-powered data analytics. This growth is driven by rising chronic diseases and cancer, increasing demand for targeted therapies, and expanding digital health integration. North America leads the market, supported by strong healthcare infrastructure and government backing, while Asia-Pacific emerges as a fast-growing region. Key companies include Novartis, Pfizer, Roche, and Illumina, with innovations in gene therapy and personalized nutrition shaping the future of healthcare.
Novartis presented new clinical data at the EULAR 2026 Congress in London, showcasing results from its immunology portfolio targeting autoimmune diseases such as polymyalgia rheumatica, Sjögren’s disease, systemic lupus erythematosus, and systemic sc...
Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients, regardless of disease volume or presentation. The PSMA...
Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), regardless of disease volume or pre...
